Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 97 articles: HTML format

Single Articles

September 2025
1. WANG DQ, Shen DX, Han N, Lu YF, et al
   Dosimetric and clinical predictors for radiation esophagitis in patients with breast cancer undergoing conventional fractionated regional nodal irradiation: A prospective study.
   Int J Cancer. 2025 Sep 18. doi: 10.1002/ijc.70161.
   PubMed     Abstract available
   
   
   
2. TANG X, Khan H, Niewola-Staszkowska K, Wuest F, et al
   Inhibition of autotaxin activity with IOA-289 decreases fibrosis in mouse E0771 breast tumors.
   Int J Cancer. 2025;157:1205-1217.
   PubMed     Abstract available
   
   
   
3. AZZI E, Bode H, Palviainen T, Hukkanen M, et al
   Long-term impact of stressful life events on breast cancer risk: A 36-year genetically informed prospective study in the Finnish Twin Cohort.
   Int J Cancer. 2025 Sep 13. doi: 10.1002/ijc.70154.
   PubMed     Abstract available
   
   
   
4. JOSHI SN, Dharpawar TS, Kulkarni SR, Chaudhari PS, et al
   Comparison of iBreastExam with clinical breast examination for early detection of breast cancer in community outreach clinics in Pune, India.
   Int J Cancer. 2025 Sep 6. doi: 10.1002/ijc.70137.
   PubMed     Abstract available
   
   
   
5. KAUKONEN D, Ploner A, Zeng E, Bergqvist J, et al
   Evaluating distant recurrence-free survival and location of metastasis in HER2+ breast cancer by ER status.
   Int J Cancer. 2025 Sep 6. doi: 10.1002/ijc.70135.
   PubMed     Abstract available
   
   
   
6. VANDRAAS KF, Hjorth S, Trewin-Nybraten CB, Ursin G, et al
   Anti-Her2 therapy patterns in metastatic breast cancer-Real-world data suggest undertreatment.
   Int J Cancer. 2025 Sep 2. doi: 10.1002/ijc.70120.
   PubMed     Abstract available
   
   
   
7. KASPER E, Boulouard F, Basset N, Golmard L, et al
   Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories.
   Int J Cancer. 2025;157:897-907.
   PubMed     Abstract available
   
   
   
8. LADO-FERNANDEZ P, Vilas JM, Fernandes T, Carneiro C, et al
   Transcriptional repression of SOX2 by p53 in cancer cells regulates cell identity and migration.
   Int J Cancer. 2025;157:980-992.
   PubMed     Abstract available
   
   
   
9. BRITO-ROCHA T, Constancio V, Leite-Silva P, Carvalho-Maia C, et al
   Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test.
   Int J Cancer. 2025;157:1006-1019.
   PubMed     Abstract available
   
   
   
10. RABE F, Getachew S, Stroetmann CY, Mezger NCS, et al
    Time to pathologic diagnosis of suspicious breast lesions: An institution-based study in five Ethiopian hospitals.
    Int J Cancer. 2025;157:876-889.
    PubMed     Abstract available
    
    
    August 2025
11. MARKIEWICZ A
    A mass cytometry-based lens on DNA damage repair in circulating tumor cells from breast cancer patients.
    Int J Cancer. 2025 Aug 29. doi: 10.1002/ijc.70105.
    PubMed    
    
    
    
12. JOHN EM, Koo J, Keegan TH, Gomez SL, et al
    Reproductive factors and risk of contralateral breast cancer by age and hormone receptor status: The California Breast Cancer Survivorship Consortium.
    Int J Cancer. 2025 Aug 16. doi: 10.1002/ijc.70089.
    PubMed     Abstract available
    
    
    
13. WU X, Qu F, Hua Y, Lu R, et al
    An open-label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2-negative metastatic breast cancer.
    Int J Cancer. 2025 Aug 11. doi: 10.1002/ijc.70079.
    PubMed     Abstract available
    
    
    
14. JOHN EM, Koo J, Keegan TH, Gomez SL, et al
    Overall and central adiposity and risk of contralateral breast cancer: The California Breast Cancer Survivorship Consortium.
    Int J Cancer. 2025 Aug 7. doi: 10.1002/ijc.70073.
    PubMed     Abstract available
    
    
    
15. CHEN Y, Salas LA, Marotti JD, Jenkins NP, et al
    Reply to: "Comments on the paper 'Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer' by Y. Chen et al.".
    Int J Cancer. 2025;157:590-591.
    PubMed    
    
    
    
16. LONNING PE, Nikolaienko O, Knappskog S
    Comments on the paper "Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer" by Y. Chen et al.
    Int J Cancer. 2025;157:588-589.
    PubMed    
    
    
    
17. LIU W, Gupta S, Gupta S
    The role of UPR-related long noncoding RNAs in development of endocrine resistance in breast cancer.
    Int J Cancer. 2025 Aug 1. doi: 10.1002/ijc.70067.
    PubMed     Abstract available
    
    
    
18. RASHID MU, Muhammad N, Arif S, Naeemi H, et al
    Genetic landscape of Pakistani familial breast cancer patients using multigene panel testing.
    Int J Cancer. 2025 Aug 1. doi: 10.1002/ijc.70070.
    PubMed     Abstract available
    
    
    July 2025
19. LIN CN, Wang JD, Huang WY, Hwang JS, et al
    Mammography screening reduced lifetime loss of employment duration and productivity for women with breast cancer: Real-world evidence of societal impacts.
    Int J Cancer. 2025 Jul 24. doi: 10.1002/ijc.70051.
    PubMed     Abstract available
    
    
    
20. CIVITA P, Mazzanti CM, Lessi F, Marchio C, et al
    Human sporadic breast carcinoma histotypes driven by the Human Betaretrovirus homologous to Mouse Mammary Tumor Virus.
    Int J Cancer. 2025;157:371-383.
    PubMed     Abstract available
    
    
    
21. HOU J, Yang F, Gao Y, Cai H, et al
    MR imaging of breast cancer: Interpretable radiomics analysis to assess treatment response and survival prognosis after neoadjuvant therapy.
    Int J Cancer. 2025 Jul 15. doi: 10.1002/ijc.35514.
    PubMed     Abstract available
    
    
    
22. JIA G, Ping J, Tao R, Long J, et al
    Integrating multi-ancestry genomic and proteomic data to identify blood risk biomarkers and target proteins for breast cancer genetic risk loci.
    Int J Cancer. 2025 Jul 14. doi: 10.1002/ijc.70041.
    PubMed     Abstract available
    
    
    
23. BEIERLEIN M, Haberle L, Nabieva N, Maass N, et al
    Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial.
    Int J Cancer. 2025 Jul 11. doi: 10.1002/ijc.70037.
    PubMed     Abstract available
    
    
    June 2025
24. WEI SQ, Leduc V, Potter B, Paradis G, et al
    Preeclampsia and risk of breast cancer: A longitudinal cohort study of tumor histology.
    Int J Cancer. 2025 Jun 25. doi: 10.1002/ijc.70025.
    PubMed     Abstract available
    
    
    
25. JENSEN A, Gottschau M, Christensen J, Lindquist S, et al
    Risk of breast cancer among women with hypo- and hyperthyroidism: Results from a large nationwide cohort study.
    Int J Cancer. 2025 Jun 23. doi: 10.1002/ijc.70007.
    PubMed     Abstract available
    
    
    
26. MENZ BD, Modi ND, Abuhelwa AY, Kuderer NM, et al
    Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials.
    Int J Cancer. 2025 Jun 21. doi: 10.1002/ijc.70020.
    PubMed     Abstract available
    
    
    
27. HOVELING LA, Heuken LP, Harfst T, Schuurman MS, et al
    Understanding delays in breast cancer diagnosis in Africa: Key insights and contributing factors.
    Int J Cancer. 2025 Jun 20. doi: 10.1002/ijc.70008.
    PubMed     Abstract available
    
    
    
28. MAHAMAT-SALEH Y, Merdas M, Viallon V, Robinot N, et al
    Association of serum metabolites and breast cancer risk: A population-based case-control study in black urban South African women.
    Int J Cancer. 2025 Jun 17. doi: 10.1002/ijc.35503.
    PubMed     Abstract available
    
    
    
29. BENDINELLI B, Danza G, Assedi M, Villanelli F, et al
    Circulating sex hormones and volumetric breast density: A prospective study in women from the EPIC Florence cohort.
    Int J Cancer. 2025;156:2294-2302.
    PubMed     Abstract available
    
    
    
30. MALLARD J, Hucteau E, Schott R, Pivot X, et al
    Tracking cancer-related fatigue during chemotherapy: Insights from a comparative cohort study of early breast cancer patients.
    Int J Cancer. 2025 Jun 10. doi: 10.1002/ijc.35508.
    PubMed     Abstract available
    
    
    
31. MUNHOZ J, Newell M, Bigras G, Goruk S, et al
    Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial.
    Int J Cancer. 2025 Jun 9. doi: 10.1002/ijc.35517.
    PubMed     Abstract available
    
    
    
32. NIEDERMAYER K, Schaffler H, Vlachos G, Greco S, et al
    Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients.
    Int J Cancer. 2025 Jun 2. doi: 10.1002/ijc.35498.
    PubMed     Abstract available
    
    
    
33. BHIMANI J, Wang P, Gallagher GB, O'Connell K, et al
    Patient factors and modifications to intended chemotherapy for women with Stages I-IIIA breast cancer.
    Int J Cancer. 2025 Jun 2. doi: 10.1002/ijc.35494.
    PubMed     Abstract available
    
    
    May 2025
34. LOAP P, Uakkas A, Bouziane J, Fourquet A, et al
    Long-term cardiac outcomes in breast cancer patients treated with helical tomotherapy: Evaluating the applicability of 3D-based dose constraints for intensity modulated radiation therapy.
    Int J Cancer. 2025 May 23. doi: 10.1002/ijc.35474.
    PubMed     Abstract available
    
    
    
35. XIE X, Chen L, Kong X, Huo Y, et al
    Comparative efficacy and safety of PD-1 versus PD-L1 inhibitors in breast cancer treatment: A systematic review and meta analysis.
    Int J Cancer. 2025;156:1936-1949.
    PubMed     Abstract available
    
    
    
36. KANG NK, Choi KH, Jeong JU, Ahn SJ, et al
    Long-term risk of major cardiac events in breast cancer patients treated with intensity-modulated and 3-dimensional conformal radiotherapy: Secondary analysis of a randomized clinical trial.
    Int J Cancer. 2025 May 9. doi: 10.1002/ijc.35476.
    PubMed     Abstract available
    
    
    
37. WANG Y, He L, Chen M, Chen L, et al
    Timing of surgery and 1-year postoperative outcomes in patients with breast cancer and preoperative COVID-19 history: A matched, longitudinal, ambidirectional cohort study.
    Int J Cancer. 2025 May 5. doi: 10.1002/ijc.35466.
    PubMed     Abstract available
    
    
    April 2025
38. MUNOZ CE, Dai WF, Cheung WY, de Oliveira C, et al
    Real-world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan-Canadian population-based cohort study.
    Int J Cancer. 2025 Apr 23. doi: 10.1002/ijc.35448.
    PubMed     Abstract available
    
    
    
39. ANDOUR L, Hagenaars SC, Vangangelt K, Aalberts J, et al
    The TESTBREAST journey: Revisiting the importance of early detection by frequent screening of women at high risk of breast cancer.
    Int J Cancer. 2025 Apr 15. doi: 10.1002/ijc.35444.
    PubMed     Abstract available
    
    
    
40. GARCIA-SAENZ JA, Spera G, Pollan M, Bermejo B, et al
    Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studi
    Int J Cancer. 2025 Apr 10. doi: 10.1002/ijc.35432.
    PubMed     Abstract available
    
    
    
41. SCHMIDT ME, Hiensch AE, Depenbusch J, Monninkhof EM, et al
    Impact of exercise on sexual health, body image, and therapy-related symptoms in women with metastatic breast cancer: The randomized controlled PREFERABLE-EFFECT trial.
    Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35429.
    PubMed     Abstract available
    
    
    
42. LARNDER AH, Manges AR, Murphy RA
    The estrobolome: Estrogen-metabolizing pathways of the gut microbiome and their relation to breast cancer.
    Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35427.
    PubMed     Abstract available
    
    
    
43. PIZZATO M, McCormack V, Dossus L, Al-Alem U, et al
    Education level and risk of breast cancer by tumor subtype in the EPIC cohort.
    Int J Cancer. 2025 Apr 1. doi: 10.1002/ijc.35413.
    PubMed     Abstract available
    
    
    
44. HUANG T, Wu D, Jiang L, Wu Z, et al
    Neuro-astrocytic network in breast cancer brain metastases: Adaptive mechanisms and novel therapeutic targets.
    Int J Cancer. 2025 Apr 1. doi: 10.1002/ijc.35421.
    PubMed     Abstract available
    
    
    March 2025
45. LU W, Yao L, Wang Y, Li F, et al
    Characterization of extrachromosomal circular DNA associated with genomic repeat sequences in breast cancer.
    Int J Cancer. 2025 Mar 26. doi: 10.1002/ijc.35423.
    PubMed     Abstract available
    
    
    
46. JALAGUIER S, Kuehn A, Petitpas C, Dulom A, et al
    The transcription factor RIP140 regulates interferon gamma signaling in breast cancer.
    Int J Cancer. 2025 Mar 10. doi: 10.1002/ijc.35405.
    PubMed     Abstract available
    
    
    February 2025
47. SCHWERD-KLEINE P, Wurth R, Cheytan T, Michel L, et al
    Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility.
    Int J Cancer. 2025 Feb 28. doi: 10.1002/ijc.35386.
    PubMed     Abstract available
    
    
    January 2025
48. GOLANI R, Kagenaar E, Jegu J, Belot A, et al
    Socio-economic inequalities in second primary cancer incidence: A competing risks analysis of women with breast cancer in England between 2000 and 2018.
    Int J Cancer. 2025 Jan 24. doi: 10.1002/ijc.35320.
    PubMed     Abstract available
    
    
    
49. ZAHWE M, Bendahhou K, Eser S, Mukherji D, et al
    Current and future burden of female breast cancer in the Middle East and North Africa region using estimates from GLOBOCAN 2022.
    Int J Cancer. 2025 Jan 10. doi: 10.1002/ijc.35325.
    PubMed     Abstract available
    
    
    
50. LUND E, Busund LR, Holden L
    Curvilinear incidence models for parity in the entire fertility range for cancers of the breast, ovary, and endometrium: A follow-up of the Norwegian 1960 Census.
    Int J Cancer. 2025 Jan 3. doi: 10.1002/ijc.35312.
    PubMed     Abstract available
    
    
    December 2024
51. RODRIGUEZ MS, Mahmoud YD, Vanzulli S, Giulianelli S, et al
    FGFR2-RUNX2 activation: An unexplored therapeutic pathway in luminal breast cancer related to tumor progression.
    Int J Cancer. 2024 Dec 28. doi: 10.1002/ijc.35302.
    PubMed     Abstract available
    
    
    
52. KOUVARAKI M, Zerdes I, Sifakis EG, Sarafidis M, et al
    Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.
    Int J Cancer. 2024 Dec 27. doi: 10.1002/ijc.35319.
    PubMed     Abstract available
    
    
    
53. THILL M, Zahn MO, Welt A, Nusch A, et al
    Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.
    Int J Cancer. 2024 Dec 20. doi: 10.1002/ijc.35296.
    PubMed     Abstract available
    
    
    
54. MOUHANNA P, Stahlberg A, Andersson D, Albu-Kareem A, et al
    Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements.
    Int J Cancer. 2024 Dec 18. doi: 10.1002/ijc.35292.
    PubMed     Abstract available
    
    
    
55. CHENG TC, Huang BM, Liao YC, Chang HS, et al
    Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4-overexpressing breast cancer cells.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35271.
    PubMed     Abstract available
    
    
    
56. CHEN Y, Salas LA, Marotti JD, Jenkins NP, et al
    Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer.
    Int J Cancer. 2024 Dec 5. doi: 10.1002/ijc.35274.
    PubMed     Abstract available
    
    
    November 2024
57. HOANG T, Lee J, Jung SY, Kim J, et al
    Determining risk-adapted starting age and interval for breast cancer screening based on reproductive and hormonal factors.
    Int J Cancer. 2024 Nov 27. doi: 10.1002/ijc.35265.
    PubMed     Abstract available
    
    
    
58. LI T, Zhang M, Zhang T, Li S, et al
    Cyclin-dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database.
    Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35255.
    PubMed     Abstract available
    
    
    
59. JIANG C, Freedman RA, Punglia RS, Jemal A, et al
    Associations of radiotherapy receipt with lung cancer risk by histological subtype among breast cancer survivors in the United States.
    Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35257.
    PubMed     Abstract available
    
    
    
60. CAO L, Ou D, Qi WX, Xu C, et al
    A randomized trial of early cardiotoxicity in breast cancer patients receiving postoperative IMRT with or without serial cardiac dose constraints.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35245.
    PubMed     Abstract available
    
    
    
61. SCHEI-ANDERSEN AJ, Hendricks LAJ, van der Post RS, Mensenkamp AR, et al
    Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single-center study.
    Int J Cancer. 2024;155:1567-1576.
    PubMed     Abstract available
    
    
    October 2024
62. NOGUCHI Y, Ino Y, Kobayashi R, Yoshimura T, et al
    Comment on "Postmarketing adverse events of tamoxifen in male and female patients with breast cancer".
    Int J Cancer. 2024 Oct 29. doi: 10.1002/ijc.35243.
    PubMed    
    
    
    
63. HOLDER EX, Bigham Z, Nelson KP, Barnard ME, et al
    Mammographic density and breast cancer risk among Black American women.
    Int J Cancer. 2024 Oct 19. doi: 10.1002/ijc.35223.
    PubMed     Abstract available
    
    
    
64. ARIBAL E, Seker ME, Guldogan N, Yilmaz E, et al
    Value of automated breast ultrasound in screening: Standalone and as a supplemental to digital breast tomosynthesis.
    Int J Cancer. 2024;155:1466-1475.
    PubMed     Abstract available
    
    
    
65. ZHENG Y, Vdovichenko N, Schurmann P, Ramachandran D, et al
    Comparative sequencing study of mismatch repair and homology-directed repair genes in endometrial cancer and breast cancer patients from Kazakhstan.
    Int J Cancer. 2024 Oct 14. doi: 10.1002/ijc.35215.
    PubMed     Abstract available
    
    
    
66. HAMAD W, Michell MJ, Myles JP, Gilbert FJ, et al
    Diagnostic performance of tomosynthesis plus synthetic mammography versus full-field digital mammography with or without tomosynthesis in breast cancer screening: A systematic review and meta-analysis.
    Int J Cancer. 2024 Oct 12. doi: 10.1002/ijc.35217.
    PubMed     Abstract available
    
    
    September 2024
67. KE C, Chen M, Lin L, Huang Y, et al
    Postmarketing adverse events of tamoxifen in male and female patients with breast cancer.
    Int J Cancer. 2024 Sep 21. doi: 10.1002/ijc.35193.
    PubMed     Abstract available
    
    
    
68. PFOB A, Surovtsova I, Kokh DB, Heil J, et al
    Use of chemotherapy and loco-regional therapy in stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study.
    Int J Cancer. 2024 Sep 18. doi: 10.1002/ijc.35189.
    PubMed     Abstract available
    
    
    
69. BARNES I, Garcia-Closas M, Gathani T, Sweetland S, et al
    A comparative analysis of risk factor associations with interval and screen-detected breast cancers: A large UK prospective study.
    Int J Cancer. 2024;155:979-987.
    PubMed     Abstract available
    
    
    
70. POISEUIL M, Molinie F, Dabakuyo-Yonli TS, Laville I, et al
    Impact of organized and opportunistic screening on excess mortality and on social inequalities in breast cancer survival.
    Int J Cancer. 2024 Sep 7. doi: 10.1002/ijc.35173.
    PubMed     Abstract available
    
    
    
71. KOON SUN PAT M, Manraj M, Manraj S
    Breast cancer survival analysis in the Republic of Mauritius by age, stage at diagnosis and molecular subtype: A retrospective cohort study.
    Int J Cancer. 2024 Sep 7. doi: 10.1002/ijc.35172.
    PubMed     Abstract available
    
    
    August 2024
72. 
    RETRACTION: High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells.
    Int J Cancer. 2024 Aug 28. doi: 10.1002/ijc.35151.
    PubMed     Abstract available
    
    
    
73. LIU B, Song Y, Xu Y, Sun Q, et al
    Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting.
    Int J Cancer. 2024 Aug 23. doi: 10.1002/ijc.35140.
    PubMed     Abstract available
    
    
    
74. KIM CE, Pereira A, Binder AM, Amarasiriwardena C, et al
    Time-specific impact of trace metals on breast density of adolescent girls in Santiago, Chile.
    Int J Cancer. 2024;155:627-636.
    PubMed     Abstract available
    
    
    
75. KINDT CK, Alves CL, Ehmsen S, Kragh A, et al
    Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.
    Int J Cancer. 2024 Aug 11. doi: 10.1002/ijc.35126.
    PubMed     Abstract available
    
    
    July 2024
76. LEREVEREND C, Kotaich N, Cartier L, De Boni M, et al
    Enhanced expression of galectin-9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapy.
    Int J Cancer. 2024 Jul 30. doi: 10.1002/ijc.35107.
    PubMed     Abstract available
    
    
    
77. 
    Expression of Concern: Induction of the Death-Promoting Gene bax-alpha Sensitizes Cultured Breast-Cancer Cells to Drug-Induced Apoptosis.
    Int J Cancer. 2024 Jul 26. doi: 10.1002/ijc.35108.
    PubMed    
    
    
    
78. GABRIELSON M, Hammarstrom M, Bergqvist J, Lang K, et al
    Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change.
    Int J Cancer. 2024;155:339-351.
    PubMed     Abstract available
    
    
    
79. JIANG C, Giaquinto AN, Jemal A, Sung H, et al
    Trends in breast cancer incidence by estrogen receptor status in the United States, 2004-2020.
    Int J Cancer. 2024 Jul 10. doi: 10.1002/ijc.35073.
    PubMed     Abstract available
    
    
    
80. BHIMANI J, O'Connell K, Persaud S, Blinder V, et al
    Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancer.
    Int J Cancer. 2024 Jul 6. doi: 10.1002/ijc.35053.
    PubMed     Abstract available
    
    
    June 2024
81. ANDREOU M, Jakalski M, Duzowska K, Filipowicz N, et al
    Prelude to malignancy: A gene expression signature in normal mammary gland from breast cancer patients suggests pre-tumorous alterations and is associated with adverse outcomes.
    Int J Cancer. 2024 Jun 8. doi: 10.1002/ijc.35050.
    PubMed     Abstract available
    
    
    May 2024
82. DE JONGE C, Schipper RJ, Walstra CJEF, Van Riet YE, et al
    Breast conserving surgery with intraoperative electron beam radiation therapy for low-risk breast cancer: Five-year follow-up of 306 patients.
    Int J Cancer. 2024 May 16. doi: 10.1002/ijc.35033.
    PubMed     Abstract available
    
    
    
83. HAN X, Liu Y, Zhang S, Li L, et al
    Improving the diagnosis of ductal carcinoma in situ with microinvasion without immunohistochemistry: An innovative method with H&E-stained and multiphoton microscopy images.
    Int J Cancer. 2024;154:1802-1813.
    PubMed     Abstract available
    
    
    
84. BAO Y, Sui X, Wang X, Qu N, et al
    Extrachromosomal circular DNA landscape of breast cancer with lymph node metastasis.
    Int J Cancer. 2024 May 1. doi: 10.1002/ijc.34985.
    PubMed     Abstract available
    
    
    April 2024
85. BRANDT C, Vo JB, Gierach GL, Cheng I, et al
    Second primary cancer risks according to race and ethnicity among U.S. breast cancer survivors.
    Int J Cancer. 2024 Apr 29. doi: 10.1002/ijc.34971.
    PubMed     Abstract available
    
    
    
86. BUDUKH A, Dora T, Sancheti S, Singh V, et al
    Outcome of early detection approach in control of breast, cervical, and oral cancer: Experience from a rural cancer center in India.
    Int J Cancer. 2024 Apr 20. doi: 10.1002/ijc.34966.
    PubMed     Abstract available
    
    
    
87. LIN YY, Gao HF, Li H, Hu Q, et al
    Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer.
    Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34945.
    PubMed     Abstract available
    
    
    
88. WANG Y, Cai W, He P, Cai Q, et al
    Clinical outcomes of coronavirus disease in patients with breast cancer treated with granulocyte colony-stimulating factor following chemotherapy: Triangulation of evidence using population-based cohort and Mendelian randomization analyses.
    Int J Cancer. 2024 Apr 1. doi: 10.1002/ijc.34914.
    PubMed     Abstract available
    
    
    March 2024
89. 
    Correction to "Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database".
    Int J Cancer. 2024 Mar 30. doi: 10.1002/ijc.34925.
    PubMed    
    
    
    
90. WU H, Wang W, Zhang Y, Chen Y, et al
    Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
    Int J Cancer. 2024 Mar 27. doi: 10.1002/ijc.34931.
    PubMed     Abstract available
    
    
    
91. SONGISO M, Nunez O, Cabanes A, Mutale M, et al
    Three-year survival of breast cancer patients attending a one-stop breast care clinic nested within a primary care health facility in sub-Saharan Africa-Zambia.
    Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34920.
    PubMed     Abstract available
    
    
    
92. DAL MASO L, Toffolutti F, De Paoli A, Giudici F, et al
    Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population-based study in Italy.
    Int J Cancer. 2024 Mar 23. doi: 10.1002/ijc.34923.
    PubMed     Abstract available
    
    
    
93. WANG T, Chai B, Chen WY, Holmes MD, et al
    Metformin and other anti-diabetic medication use and breast cancer incidence in the Nurses' Health Studies.
    Int J Cancer. 2024 Mar 22. doi: 10.1002/ijc.34917.
    PubMed     Abstract available
    
    
    
94. KREGTING LM, Vrancken Peeters NJMC, Clarijs ME, Koppert LB, et al
    Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost-effectiveness.
    Int J Cancer. 2024 Mar 13. doi: 10.1002/ijc.34899.
    PubMed     Abstract available
    
    
    
95. LUFTNER D, Schuetz F, Schneeweiss A, Hartkopf A, et al
    Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34912.
    PubMed     Abstract available
    
    
    
96. LIU X, Xie X, Sui C, Liu X, et al
    Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: Mechanisms and clinical implications.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34900.
    PubMed     Abstract available
    
    
    February 2024
97. TANG T, Yu H, Xu S, Zhong Y, et al
    Causal effects of endometriosis on cancer risk: A Mendelian randomization study.
    Int J Cancer. 2024 Feb 7. doi: 10.1002/ijc.34876.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.